Literature DB >> 30690050

New insights into the utility of omalizumab.

Juan Carlos Cardet1, Thomas B Casale2.   

Abstract

Entities:  

Keywords:  FcεRIα; IgE; allergy; antiviral immunity; asthma; biologic therapy; chronic urticaria; food allergy; immunotherapy; mAb

Mesh：

Substances：

Year:  2019        PMID： 30690050      PMCID： PMC6939862          DOI： 10.1016/j.jaci.2019.01.016

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  36 in total

1.  Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.

Authors:  Janine Gericke; Martin Metz; Tatevik Ohanyan; Karsten Weller; Sabine Altrichter; Per Stahl Skov; Sidsel Falkencrone; Janko Brand; Arno Kromminga; Tomasz Hawro; Martin K Church; Marcus Maurer
Journal:  J Allergy Clin Immunol       Date:  2016-11-09       Impact factor: 10.793

2.  Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.

Authors:  S Broesby-Olsen; H Vestergaard; C G Mortz; B Jensen; T Havelund; A P Hermann; F Siebenhaar; M B Møller; T K Kristensen; C Bindslev-Jensen
Journal:  Allergy       Date:  2017-07-27       Impact factor: 13.146

3.  Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

Authors:  Philippe Gevaert; Lien Calus; Thibaut Van Zele; Katrien Blomme; Natalie De Ruyck; Wouter Bauters; Peter Hellings; Guy Brusselle; Dirk De Bacquer; Paul van Cauwenberge; Claus Bachert
Journal:  J Allergy Clin Immunol       Date:  2012-09-27       Impact factor: 10.793

4.  The immunology of asthma.

Authors:  Bart N Lambrecht; Hamida Hammad
Journal:  Nat Immunol       Date:  2015-01       Impact factor: 25.606

5.  Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.

Authors:  Ann Esquivel; William W Busse; Agustin Calatroni; Alkis G Togias; Kristine G Grindle; Yury A Bochkov; Rebecca S Gruchalla; Meyer Kattan; Carolyn M Kercsmar; G Khurana Hershey; Haejin Kim; Petra Lebeau; Andrew H Liu; Stanley J Szefler; Stephen J Teach; Joseph B West; Jeremy Wildfire; Jaqueline A Pongracic; James E Gern
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

6.  Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.

Authors:  A V Marzano; G Genovese; G Casazza; M T Fierro; P Dapavo; N Crimi; S Ferrucci; P Pepe; S Liberati; P D Pigatto; A Offidani; E Martina; G Girolomoni; M Rovaris; C Foti; L Stingeni; A Cristaudo; G W Canonica; E Nettis; R Asero
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-12-07       Impact factor: 6.166

7.  Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria.

Authors:  T A Kanters; H B Thio; L Hakkaart
Journal:  Br J Dermatol       Date:  2018-06-15       Impact factor: 9.302

8.  A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.

Authors:  Robert A Wood; Jennifer S Kim; Robert Lindblad; Kari Nadeau; Alice K Henning; Peter Dawson; Marshall Plaut; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2015-11-12       Impact factor: 10.793

9.  Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma.

Authors:  Prathap Pillai; Yih-Chih Chan; Shih-Ying Wu; Line Ohm-Laursen; Clare Thomas; Stephen R Durham; Andrew Menzies-Gow; Raj K Rajakulasingam; Sun Ying; Hannah J Gould; Chris J Corrigan
Journal:  Eur Respir J       Date:  2016-10-20       Impact factor: 16.671

10.  Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.

Authors:  T B Casale; B E Chipps; K Rosén; B Trzaskoma; T Haselkorn; T A Omachi; S Greenberg; N A Hanania
Journal:  Allergy       Date:  2017-09-23       Impact factor: 13.146
View more
  9 in total

1.  The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment.

Authors:  Emel Atayik; Gokhan Aytekin
Journal:  Rev Fr Allergol (2009)       Date:  2022-06-13

Review 2.  Prevention of Asthma: Targets for Intervention.

Authors:  Michelle C Maciag; Wanda Phipatanakul
Journal:  Chest       Date:  2020-04-21       Impact factor: 9.410

3.  Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.

Authors:  Simona Barni; Mattia Giovannini; Giulia Liccioli; Lucrezia Sarti; Anna Gissi; Paolo Lionetti; Francesca Mori
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

Review 4.  Pediatric usage of Omalizumab: A promising one.

Authors:  Lin Yu; Huishan Zhang; Jianwei Pan; Leping Ye
Journal:  World Allergy Organ J       Date:  2021-12-11       Impact factor: 4.084

5.  Immunoglobulin E-Dependent Activation of Immune Cells in Rhinovirus-Induced Asthma Exacerbation.

Authors:  Toshiaki Kawakami; Kazumi Kasakura; Yu Kawakami; Tomoaki Ando
Journal:  Front Allergy       Date:  2022-02-22

6.  ERS International Virtual Congress 2021: Highlights from the Turkish Thoracic Society Early Career Members.

Authors:  Merve Yumrukuz Şenel; Dilek Karadoğan; Ilgım Vardaloğlu; Elif Develi; Selma Çelik; Mina Hızal; Beste Özsezen; Aslı Öncel; İlknur Can; Nur Hürsoy; Kübra Uyar; Fatma Gülsüm Karakaş; Berrin Er; Pelin Asfuroğlu; Tuğba Ramaslı Gürsoy; Tuğba Şişmanlar Eyüboğlu; Eylül Pınar Çakır; Dilber Ademhan; Selen Karaoğlanoğlu; Nagehan Emiralioğlu; Nilufer Aylin Acet Öztürk; Feride Marim; Özge Aydın Güçlü; Nazli Çetin; Dilara Ömer Topçu; Pınar Çelik; Metin Akgün
Journal:  Turk Thorac J       Date:  2022-03

Review 7.  Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab.

Authors:  Francesco Menzella; Giulia Ghidoni; Carla Galeone; Silvia Capobelli; Chiara Scelfo; Nicola Cosimo Facciolongo
Journal:  Biomedicines       Date:  2021-03-30

8.  A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation.

Authors:  Julia Schanin; Simon Gebremeskel; Wouter Korver; Rustom Falahati; Melina Butuci; Tatt Jhong Haw; Prema M Nair; Gang Liu; Nicole G Hansbro; Philip M Hansbro; Erik Evensen; Emily C Brock; Alan Xu; Alan Wong; John Leung; Christopher Bebbington; Nenad Tomasevic; Bradford A Youngblood
Journal:  Mucosal Immunol       Date:  2020-08-19       Impact factor: 7.313

Review 9.  Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective.

Authors:  Michele Ghezzi; Elena Pozzi; Luisa Abbattista; Luisa Lonoce; Gian Vincenzo Zuccotti; Enza D'Auria
Journal:  Children (Basel)       Date:  2021-12-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.